
Video
Bladder Cancer at ASCO 2026: A New Standard in Non-Muscle Invasive Disease, Intravesical Approaches in Muscle-Invasive Disease, and Three and a Half Years of Enfortumab Vedotin Data
Bladder cancer management in 2026 has been transformed at multiple stages of disease: in non-muscle invasive disease by the arrival of immune checkpoint inhibitors added to BCG
By Rosa M. Nadal Rios, MD, PhD





























